| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |